In the BioHarmony Drug Report Database
Ipilimumab
Yervoy (ipilimumab) is an antibody pharmaceutical. Ipilimumab was first approved as Yervoy on 2011-03-25. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms, malignant mesothelioma, melanoma, non-small-cell lung carcinoma, and renal cell carcinoma. The pharmaceutical is active against cytotoxic T-lymphocyte protein 4.
Trade Name
|
Yervoy |
|---|---|
Common Name
|
ipilimumab |
ChEMBL ID
|
CHEMBL1789844 |
Indication
|
colorectal neoplasms, malignant mesothelioma, melanoma, non-small-cell lung carcinoma, renal cell carcinoma |
Drug Class
|
Monoclonal antibodies |
Image (chem structure or protein)
